Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Clin Immunol ; 133(3): 295-302, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19793681

ABSTRACT

Following hematopoietic stem cell transplantation (HSCT), thymic reconstitution of peripheral T lymphocytes is essential to avoid a chronically immunodeficient state and disease recurrence. The purpose of this study was to determine if children and adolescents with treatment refractory SSc, awaiting HSCT, have sufficient thymic function to reconstitute T lymphocyte function after transplantation. Thirteen children with systemic scleroderma were enrolled and assessed by physical exam, chest MRI, measurement of autoantibodies, B and T cell immuno-phenotyping, and quantization of T cell receptor rearrangement excision circles (TREC) as a marker of thymopoiesis. MRI detected thymic tissue in 9/13 children. TREC levels were detectable in all but one child but were significantly reduced (p<0.001) when compared to a control population. SSc patients also had a reduced percentage of naïve (CD45RA+CD31+) CD4+ T lymphocytes, further indicating diminished thymopoiesis. Our data suggest that thymic function in children with SSc might be insufficient for an adequate immunoreconstitution following transplantation in some patients. A thorough evaluation of immune and thymic functions to identify those patients prior to HSCT is recommended.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Receptors, Antigen, T-Cell/immunology , Scleroderma, Systemic/immunology , T-Lymphocyte Subsets/immunology , Thymus Gland/immunology , Adolescent , Antibodies, Antinuclear/blood , Antibodies, Antinuclear/immunology , Cell Proliferation , Child , Female , Humans , Leukocyte Common Antigens/blood , Leukocyte Common Antigens/immunology , Linear Models , Magnetic Resonance Imaging , Male , Organ Size/immunology , Scleroderma, Systemic/therapy , Thymus Gland/anatomy & histology , Young Adult
3.
Transplant Proc ; 36(2): 379-80, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15050165

ABSTRACT

AIM: To review the incidence, timing, and outcome of infectious enteritis after intestinal transplantation (IT). METHOD: A retrospective review of all patients undergoing IT at a single institution between 1991 and 2003 was analyze with standard statistical tools. RESULTS: Among 33 IT recipients, 13 (39%) developed 20 culture- or biopsy-proven episodes of infectious enteritis. The recipient demographics were 77% men and median age 2.6 years. Infections were diagnosed at a median of 76 days (32 to 1800) after IT. There were 14 viral (CMV one, rotavirus eight, adenovirus four, EBV one, three bacterial (Clostridium difficile), and three other infections (Giardia lamblia one, cryptosporidium two). Complete resolution was achieved in 17 (94%) infectious after appropriate antimicrobial or conservative therapy. Interestingly, there were six rejection episodes following infectious enteritis. Grafts were lost to rejection after rotaviral enteritis (n = 1) and adenoviral enteritis misdiagnosed as rejection (n = 1). Patient and graft survival were not adversely affected by infections. CONCLUSIONS: Infectious enteritis occurs frequently after IT. Viral agents are the cause in two-thirds of cases. With supportive care and appropriate treatment, resolution is possible in the majority of cases. Differentiating rejection and infection by histopathology can be difficult.


Subject(s)
Bacterial Infections/epidemiology , Enteritis/epidemiology , Intestines/transplantation , Virus Diseases/epidemiology , Adult , Child , Female , Humans , Intestines/microbiology , Male , Postoperative Complications/microbiology , Postoperative Complications/virology , Retrospective Studies , Time Factors , Treatment Outcome
4.
AIDS Res Hum Retroviruses ; 17(16): 1489-500, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11709093

ABSTRACT

Cell motility is likely to play a pivotal role in HIV infection by promoting the dissemination of infected cells. On the basis of observations indicating an interaction between HIV-1 Gag and target cell filamentous actin, we hypothesized that these interactions would promote cell motility of HIV-infected cells. Indeed, we have found that HIV-1 infection enhances the chemotactic response of macrophages. To specifically investigate the significance of the interactions between Gag and cellular actin, we transfected NIH 3T3 fibroblasts and HeLa cells with a construct that permits the expression of HIV-1 Gag in the absence of any other viral protein. Fractionation experiments showed that Gag was present in cytoskeletal fraction containing long actin filaments and in a high-speed postcytoskeletal fraction with short actin filaments. We have also localized HIV-1 Gag to the lamellipodia of chemoattractant-stimulated cells. Significantly, the motility of Gag-expressing cells was enhanced in chemotaxis assays. In vitro mutagenesis experiments showed that HIV-1 Gag binds filamentous actin through the nucleocapsid domain (NC). An NC-green fluorescent protein fusion had the same cellular distribution as the complete protein, and its expression increased cell motility. These data suggest that interactions between HIV-1 Gag and actin in infected cells enhance cell motility. Ultimately this enhanced motility of infected cells could promote the dissemination of virus into the brain and other tissues.


Subject(s)
Chemotaxis/physiology , Cytoskeleton/metabolism , Gene Products, gag/metabolism , HIV-1/pathogenicity , Macrophages/physiology , Nucleocapsid/metabolism , 3T3 Cells/physiology , 3T3 Cells/virology , Actins/metabolism , Animals , Gene Products, gag/genetics , HIV-1/physiology , HeLa Cells/physiology , HeLa Cells/virology , Humans , Macrophages/virology , Mice , Monocytes/physiology , Monocytes/virology , Transfection
5.
J Infect Dis ; 183(12): 1732-8, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11372025

ABSTRACT

In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine, lamivudine (3TC), nevirapine (Nvp), nelfinavir (Nfv), and ritonavir (Rtv). Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable. Drug resistance mutations were assessed before study treatment (baseline) and at virologic failure. Zdv, ddI, and ddC mutations were detected frequently at baseline but were not associated with virologic failure. Children with drug resistance mutations at baseline had greater reductions in virus load over time than did children who did not. Nvp and 3TC mutations were detected frequently at virologic failure, and Nvp mutations were more common among children receiving 3-drug versus 4-drug Nvp-containing regimens. Children who were maintained on their study regimen after virologic failure accumulated additional Nvp and 3TC mutations plus Rtv and Nfv mutations. However, Rtv and Nfv mutations were detected at unexpectedly low rates.


Subject(s)
Anti-HIV Agents/pharmacology , HIV Infections/drug therapy , HIV-1/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Adolescent , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Child , Child, Preschool , Cohort Studies , Drug Resistance, Microbial/genetics , Female , Genotype , HIV Infections/genetics , HIV Infections/virology , HIV-1/genetics , Humans , Infant , Lamivudine/pharmacology , Lamivudine/therapeutic use , Male , Mutation , Nelfinavir/pharmacology , Nelfinavir/therapeutic use , Nevirapine/pharmacology , Nevirapine/therapeutic use , RNA, Viral/blood , Reverse Transcriptase Inhibitors/therapeutic use , Ritonavir/pharmacology , Ritonavir/therapeutic use , Stavudine/pharmacology , Stavudine/therapeutic use , Treatment Failure , Viral Load
6.
J Clin Microbiol ; 39(4): 1254-7, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11283037

ABSTRACT

The ViroSeq HIV-1 Genotyping System is a commercially available, integrated sequence-based system for analysis of human immunodeficiency virus type 1 (HIV-1) drug resistance. We evaluated the performance of this system by analyzing HIV-1 in pediatric plasma samples. Plasma samples from children 4 months to 17 years of age were obtained from a clinical trial protocol (PACTG 377). Children in PACTG 377 were randomized to four treatment arms, including different combinations of antiretroviral drugs. HIV-1 genotyping was performed using samples collected prior to antiretroviral therapy (baseline) and at the time of virologic failure. Performance of the genotyping system was compared in three university laboratories. A total of 196 samples were analyzed, including 135 baseline and 61 failure samples. Plasma volumes ranged from 0.05 to 0.5 ml, and viral loads ranged from 1,084 to 3,484,991 copies/ml. PCR products suitable for sequencing were obtained for 192 of the 196 samples. Complete sequences for protease and reverse transcriptase were obtained for all of these 192 samples. For 180 samples, data were obtained from both DNA strands for the entire region analyzed. There was no evidence of sample cross-contamination based on phylogenetic analysis of HIV-1 sequences. Performance of the genotyping system was similar in three laboratories. This genotyping system performs well for analysis of HIV-1 in pediatric plasma samples, including those with low volume and low viral load. The availability of this system should facilitate studies of HIV-1 drug resistance.


Subject(s)
Anti-HIV Agents/pharmacology , HIV Infections/virology , HIV-1 , Reverse Transcriptase Inhibitors/pharmacology , Adolescent , Anti-HIV Agents/therapeutic use , Child , Child, Preschool , Drug Resistance, Microbial/genetics , Drug Therapy, Combination , Genotype , HIV Infections/drug therapy , HIV Protease/genetics , HIV Reverse Transcriptase/genetics , HIV-1/classification , HIV-1/drug effects , HIV-1/genetics , Humans , Infant , Phylogeny , RNA, Viral/blood , Reagent Kits, Diagnostic , Reverse Transcriptase Inhibitors/therapeutic use , Sequence Analysis, DNA
7.
Clin Infect Dis ; 31(5): 1144-8, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11073743

ABSTRACT

Mycotic aneurysms of the aorta caused by fungi are uncommon. We describe an unusual case of aortic aneurysm infection caused by Aspergillus terreus, which most likely spread from an adjacent pulmonary focus. Successful treatment included partial pneumonectomy, resection of the aneurysm with graft repair, and prolonged sequential administration of amphotericin B and itraconazole. A review of the published experience with aortic aneurysms caused by Aspergillus species is also presented. When invasive aspergillosis is suspected in proximity to areas with major vascular structures in immunocompromised patients, further investigation to rule out vascular invasion may be warranted. If the diagnosis is confirmed, aggressive and prompt treatment with antifungal agents combined with surgical debridement is essential to improve outcome.


Subject(s)
Aneurysm, Infected/pathology , Aortic Aneurysm/pathology , Aspergillosis/microbiology , Aspergillus/isolation & purification , Aneurysm, Infected/etiology , Aortic Aneurysm/etiology , Aspergillosis/complications , Child , Humans , Male
8.
AIDS Res Hum Retroviruses ; 16(12): 1113-21, 2000 Aug 10.
Article in English | MEDLINE | ID: mdl-10954886

ABSTRACT

One hundred eighty-one antiretroviral-experienced, protease inhibitor-naive, clinically stable HIV-infected children between 4 months and 17 years of age were randomly assigned to receive one of four combination regimens to evaluate the change in plasma HIV RNA, safety, and tolerance when changing antiretroviral therapy to a protease inhibitor-containing combination regimen. All four regimens contained stavudine; in addition children received nevirapine plus ritonavir, lamivudine plus nelfinavir, nevirapine plus nelfinavir, or lamivudine plus nevirapine plus nelfinavir. Twelve additional children chose to receive stavudine plus lamivudine plus nelfinavir, with nelfinavir given bid, rather than tid as for the main regimens. Overall, 51% (89/176; 95% CI 43-58%) of the children on the randomized portion of the study had an HIV RNA response (< or =400 copies/ml) on at least two of the three HIV RNA determinations taken at Weeks 8, 12, and 16. At Week 24 the proportion of children with an HIV RNA response still on initial therapy was 47% (83/176; 95% CI 40-55%) and ranged from 41 to 61% for the four randomized treatment arms. Rash was frequently seen (27%) on the treatment arms containing nevirapine. At Week 24 64% (7/11, 95% CI 31-89%) of the children on the bid nelfinavir combination regimen were still on initial therapy with an HIV RNA response as compared with 46% (23/50; 95% CI 32-61%) on the corresponding tid nelfinavir combination regimen. A change in antiretroviral therapy to a protease inhibitor-containing regimen was associated with a virological response rate of approximately 50% for this patient population.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Nelfinavir/therapeutic use , Nevirapine/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Ritonavir/therapeutic use , Stavudine/therapeutic use , Child , Child, Preschool , Drug Therapy, Combination , Ethnicity , Female , Humans , Infant , Male , Puerto Rico , RNA, Viral/blood , Racial Groups , Time Factors , United States , Viral Load
9.
J Infect Dis ; 182(3): 751-7, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10950768

ABSTRACT

Highly active antiretroviral therapy (HAART) suppresses plasma viremia in most patients with human immunodeficiency virus (HIV) infection. Prospective study of HIV-infected children (n=27) shows that, in 8 of 12 who responded to HAART (>/=0.5 log reduction in plasma HIV RNA), HAART restricted the number of coreceptors used by the predominant HIV isolate (mean number of coreceptors used at baseline was 4, vs. 1 coreceptor used at 6 months after treatment). This decrease was most striking in 6 of 8 children whose HIV coreceptor tropism changed from X4-tropic at baseline to R5-tropic. In 6 of 10 children tested, with plasma HIV RNA levels of <50 copies/mL, R5-tropic virus was isolated from CD4 T cell reservoirs. All the responding children had a significant increase in naive CD4 T cells (P<.05). These results show that persistent HIV T cell reservoirs are present in children and that HAART may influence the number and type of coreceptors used by the predominant virus isolate.


Subject(s)
CD4-Positive T-Lymphocytes/virology , HIV Infections/virology , HIV-1 , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolism , Virus Replication , Adolescent , Cell Differentiation , Child , Coculture Techniques , Female , HIV Infections/drug therapy , Humans , Immunophenotyping , Infant , Lamivudine/administration & dosage , Lamivudine/therapeutic use , Leukocytes, Mononuclear/virology , Male , Nelfinavir/administration & dosage , Nelfinavir/therapeutic use , Prospective Studies , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/therapeutic use , Ritonavir/administration & dosage , Ritonavir/therapeutic use , Stavudine/administration & dosage , Stavudine/therapeutic use , Viral Load , Zidovudine/administration & dosage , Zidovudine/therapeutic use
10.
Clin Infect Dis ; 28(5): 1109-18, 1999 May.
Article in English | MEDLINE | ID: mdl-10452644

ABSTRACT

An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1)-infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20-30 mg/kg yielded drug exposures comparable to those seen in adults. The drug was well tolerated; mild diarrhea was the primary toxic effect observed. Seventy-one percent (39) of the 55 evaluable subjects had an initial decrease in plasma HIV-1 RNA, of at least 0.7 log10 copies/mL; suppression of plasma HIV-1 RNA levels to < 400 copies/mL was observed in 15. Children who began taking at least one new reverse transcriptase inhibitor near the time when nelfinavir mesylate was started, and those with a > or = 24% proportion of CD4 lymphocytes, had a greater chance of achieving and maintaining a decline in plasma HIV-1 RNA to < 400 copies/mL. Suppression of viremia was achieved in children as young as 3 months of age.


Subject(s)
HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV-1 , Nelfinavir/therapeutic use , Adolescent , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count/drug effects , Child , Child, Preschool , Drug Therapy, Combination , Female , HIV Protease Inhibitors/adverse effects , HIV Protease Inhibitors/pharmacokinetics , HIV-1/drug effects , HIV-1/isolation & purification , Humans , Infant , Male , Nelfinavir/adverse effects , Nelfinavir/pharmacokinetics , RNA, Viral/blood , Reverse Transcriptase Inhibitors/therapeutic use
11.
Clin Immunol ; 92(1): 25-33, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10413650

ABSTRACT

Acute HIV infection is characterized by the appearance of high concentrations of virus in the peripheral blood. In adults, this high-level viremia spontaneously abates after several weeks. In contrast, after perinatal infection of infants, blood virus levels remain high for many months, during which the concentration of circulating CD4+ lymphocytes remains well above normal values for adults. Here we suggest an explanation for these differences, based on developmental factors including somatic growth and immunological ontogeny. Flow cytometric analysis revealed that at birth the thymus contains elevated levels of mature T lymphocytes, compared to the thymus after 3 months of age. A mathematical model is proposed incorporating immunological and virological data from longitudinally evaluated infants who acquired infection at the time of birth. This model explains the pattern of high-level viremia in infants as resulting from the replication of HIV within the progressively expanding lymphoid cell mass.


Subject(s)
HIV Infections/immunology , Adult , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/virology , HIV Infections/blood , HIV Infections/transmission , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Lymphocyte Count , Lymphocytes/virology , Models, Immunological , Viral Load , Viremia/immunology , Virus Replication
12.
Pediatrics ; 103(4 Pt 1): 711-8, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10103291

ABSTRACT

CONTEXT: Despite growing concern over the escalating antimicrobial resistance problem, physicians continue to inappropriately prescribe. It has been suggested that a major determinant of pediatrician antimicrobial prescribing behavior is the parental expectation that a prescription will be provided. OBJECTIVES: To explore the extent to which parental previsit expectations and physician perceptions of those expectations are associated with inappropriate antimicrobial prescribing; and to explore the relationship between fulfillment of expectations and parental visit-specific satisfaction. DESIGN: Previsit and postvisit survey of parents and postvisit survey of physicians. SETTING: Two private pediatric practices, one community based and one university based. PARTICIPANTS: Ten physicians (response rate = 77%), and a consecutive sample of 306 eligible parents (response rate = 86%) who were attending sick visits for their children between October 1996 and March 1997. Parents were screened for eligibility in the waiting rooms of the two practices and were invited to participate if they spoke and read English and their child was 2 to 10 years old, had a presenting complaint of ear pain, throat pain, cough, or congestion, was off antimicrobial therapy for the past 2 weeks, and was seeing one of the participating physicians. MAIN OUTCOME MEASURES: Antimicrobial prescribing decision, probability of assigning a bacterial diagnosis, and parental visit-specific satisfaction. RESULTS: Based on multivariate analysis, physicians' perceptions of parental expectations for antimicrobials was the only significant predictor of prescribing antimicrobials for conditions of presumed viral etiology; when physicians thought a parent wanted an antimicrobial, they prescribed them 62% of the time versus 7% of the time when they did not think the parent wanted antimicrobials. However, physician antimicrobial prescribing behavior was not associated with actual parental expectations for receiving antimicrobials. In addition, when physicians thought the parent wanted an antimicrobial, they were also significantly more likely to give a bacterial diagnosis (70% of the time versus 31% of the time). Failure to meet parental expectations regarding communication events during the visit was the only significant predictor of parental satisfaction. Failure to provide expected antimicrobials did not affect satisfaction. CONCLUSIONS: The antibiotic resistance epidemic should lead to immediate replication of this study in a larger more generalizable population. If inaccurate physician perceptions of parent desires for antimicrobials for viral infections are confirmed, then an intervention to change the way physicians acquire this set of perceptions should be undertaken.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Health Services Misuse/statistics & numerical data , Parents/psychology , Pediatrics/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Adult , Attitude to Health , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Logistic Models , Male , Multivariate Analysis , Patient Satisfaction , Virus Diseases/drug therapy
14.
Circ Res ; 83(7): 738-42, 1998 Oct 05.
Article in English | MEDLINE | ID: mdl-9758644

ABSTRACT

Cardiomyopathy associated with HIV-1 infection is a well-recognized complication. However, it is unknown whether direct cardiomyocyte infection is involved in the pathogenesis of the cardiomyopathy. An HIV-1-based lentiviral vector and wild-type HIV-1 were used to infect human fetal cardiac myocytes in a primary culture. Quantitative polymerase chain reaction, viral p24 antigen determination, and immunofluorescence were used to detect the synthesis of HIV-1 DNA and proteins after the infection. High-efficiency infection occurred using the HIV-1-based lentiviral vector, although no infection occurred with the wild-type HIV-1 strain. Dual-labeling immunofluorescence for HIV-1 proteins and myosin confirmed that cardiomyocytes were infected. This in vitro analysis suggests that direct myocyte infection with wild-type HIV-1 may not be involved in the pathogenesis of HIV-1 cardiomyopathy. However, HIV-1-based vectors may prove useful for ex vivo cardiovascular gene therapy.


Subject(s)
Acquired Immunodeficiency Syndrome/genetics , Fetal Heart/pathology , Genetic Vectors , HIV-1 , Cells, Cultured , Fetal Diseases/genetics , Humans , Vesicular stomatitis Indiana virus/genetics , Viral Envelope Proteins/genetics
15.
J Infect Dis ; 178(2): 375-87, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9697717

ABSTRACT

The time of perinatal human immunodeficiency virus type 1 (HIV-1) transmission and the pattern of early plasma viremia as predictors of disease progression were evaluated in infected infants followed from birth. Cox proportional hazards modeling demonstrated that a 1-log higher HIV-1 RNA copy number at birth was associated with a 40% increase in the relative hazard (RH) of developing CDC class A or B symptoms (P = .004), a 60% increase in developing AIDS (P = .01), and an 80% increase in the of risk death (P = .023) over the follow-up period of up to 8 years. The peak HIV-1 RNA copy number for infants during primary viremia was also predictive of progression to AIDS (RH, 9.9; 95% confidence interval [95% CI], 1.8-54.1; P = .008) and death (RH, 6.9; 95% CI, 1.1-43.8; P = .04). The results indicate that high levels of HIV-1 RNA at birth and during primary viremia are associated with early onset of symptoms and rapid disease progression to AIDS and death in perinatally infected children.


Subject(s)
HIV Infections/transmission , HIV Infections/virology , HIV-1 , RNA, Viral/blood , Viral Load , Acquired Immunodeficiency Syndrome/physiopathology , Acquired Immunodeficiency Syndrome/virology , Age of Onset , Anti-HIV Agents/therapeutic use , Child , Child, Preschool , Follow-Up Studies , HIV Infections/drug therapy , HIV Infections/immunology , HIV-1/genetics , Humans , Infant , Infant, Newborn , Longitudinal Studies , Prognosis , Prospective Studies , Reverse Transcriptase Inhibitors/therapeutic use , Time Factors , Zidovudine/therapeutic use
17.
Science ; 280(5366): 1073-7, 1998 May 15.
Article in English | MEDLINE | ID: mdl-9582120

ABSTRACT

Detection of human immunodeficiency virus-type 1 (HIV-1) on only one or a few occasions in infants born to infected mothers has been interpreted to indicate that infection may be transient rather than persistent. Forty-two cases of suspected transient HIV-1 viremia among 1562 perinatally exposed seroreverting infants and one mother were reanalyzed. HIV-1 env sequences were not found in specimens from 20; in specimens from 6, somatic genetic analysis revealed that specimens were mistakenly attributed to an infant; and in specimens from 17, phylogenetic analysis failed to demonstrate the expected linkage between the infant's and the mother's virus. These findings argue that transient HIV-1 infection, if it exists, will only rarely be satisfactorily documented.


Subject(s)
HIV Infections/virology , HIV-1/genetics , HIV-1/isolation & purification , Specimen Handling , DNA, Viral/analysis , DNA, Viral/genetics , Diagnostic Errors , Equipment Contamination , Female , Genes, env , HIV Infections/immunology , HIV Infections/transmission , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Molecular Sequence Data , Phylogeny , Polymerase Chain Reaction , RNA, Viral/analysis , T-Lymphocytes, Cytotoxic/immunology , Viremia/virology
18.
J Virol ; 72(5): 4403-7, 1998 May.
Article in English | MEDLINE | ID: mdl-9557731

ABSTRACT

The human immunodeficiency virus type 1 capsid protein contains a conserved P217X4PX2PX5P231 motif. Mutation at Pro-222 decreases virion incorporation of cyclophilin A, while mutation at Pro-231 abolishes infectivity. Although viral RNA incorporation and protease cleavage of the Gag precursor were not affected by these mutations, cryoelectron microscopy revealed a loss of virion maturation in P231A particles.


Subject(s)
HIV-1/genetics , HIV-1/ultrastructure , Mutagenesis, Site-Directed , Peptidylprolyl Isomerase/metabolism , Binding Sites , Cell Line , Endopeptidases/metabolism , Gene Products, gag/metabolism , HIV-1/metabolism , HIV-1/physiology , Humans , Microscopy, Electron , Virion/ultrastructure , Virus Replication
19.
J Virol ; 72(1): 303-8, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9420228

ABSTRACT

Gag polyprotein-mediated incorporation of cellular cyclophilin A (CyPA) into virions is essential for the formation of infectious human immunodeficiency virus type 1 (HIV-1) virions. Either a point mutation in Gag (P222A) or drugs which bind CyPA decrease virion incorporation of CyPA and interfere with HIV-1 replication. We have found that lymphoid cells varied greatly in their CyPA content and that cells with high CyPA content supported the replication of P222A HIV-1 Gag mutants. These experiments demonstrated that a higher cellular CyPA content of some cells was able to compensate for the decreased binding affinity of P222A mutant Gag for CyPA, allowing virus replication to occur.


Subject(s)
Genes, gag , HIV-1/genetics , HIV-1/physiology , Peptidylprolyl Isomerase/metabolism , Point Mutation , Virus Replication/genetics , Virus Replication/physiology , Animals , Base Sequence , Cell Line , DNA, Viral/biosynthesis , DNA, Viral/genetics , Humans , In Vitro Techniques , Lymphocytes/metabolism , Lymphocytes/virology
20.
N Engl J Med ; 336(19): 1343-9, 1997 May 08.
Article in English | MEDLINE | ID: mdl-9134874

ABSTRACT

BACKGROUND: In infants and children with maternally acquired human immunodeficiency virus type 1 (HIV-1) infection, treatment with a single antiretroviral agent has limited efficacy. We evaluated the safety and efficacy of a three-drug regimen in a small group of maternally infected infants. METHODS: Zidovudine, didanosine, and nevirapine were administered in combination orally to eight infants 2 to 16 months of age. The efficacy of antiretroviral treatment was evaluated by serial measurements of plasma HIV-1 RNA, quantitative plasma cultures, and quantitative cultures of peripheral-blood mononuclear cells. RESULTS: The three-drug regimen was well tolerated, without clinically important adverse events. Within four weeks, there were reductions in plasma levels of HIV-1 RNA of at least 96 percent (1.5 log) in seven of the eight study patients. Over the 6-month study period, replication of HIV-1 was controlled in two infants who began therapy at 2 1/2 months of age. Plasma RNA levels were reduced by 0.5 to 1.5 log in five of the other six infants. CONCLUSIONS: Although further observations are needed, it appears that in infants with maternally acquired HIV-1 infection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sustained efficacy against HIV-1.


Subject(s)
Anti-HIV Agents/therapeutic use , Didanosine/therapeutic use , HIV Infections/drug therapy , HIV-1 , Pyridines/therapeutic use , Zidovudine/therapeutic use , Administration, Oral , Anti-HIV Agents/blood , CD4 Lymphocyte Count/drug effects , Drug Therapy, Combination , Female , HIV Infections/immunology , HIV Infections/virology , HIV-1/drug effects , HIV-1/isolation & purification , Humans , Infant , Infectious Disease Transmission, Vertical , Male , Nevirapine , Pyridines/blood , RNA, Viral/blood , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL
...